Celcuity Q1 net loss $21.6M; Phase 3 VIKTORIA-1 on track for H2 2024 data

Celcuity Inc.

2024-Q1 EPS reported -$0.64

Net loss $21.6M ($0.64/sh) vs $11.9M ($0.55/sh) in Q1 2023; cash $177.7M expected runway into H1 2026.
Phase 3 VIKTORIA-1 on track: topline PIK3CA wild-type data H2 2024; mutant sub-group H1 2025.
First patient dosed in Phase 1b/2 trial of gedatolisib + darolutamide for mCRPC; prelim data expected H1 2025.
Appointed Eldon Mayer as CCO in Feb 2024 to prepare for potential gedatolisib launch.
R&D expenses $20.7M (up $9.4M YoY) driven by VIKTORIA-1 and new trial initiation.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Celcuity Inc. reported the first quarter ended March 31, 2024 results: net income Net loss for the first quarter of 2024 was $21.6 million, or $0.64 loss per share, EPS $0.64 loss per share.

Period: the first quarter ended March 31, 2024
Net income: Net loss for the first quarter of 2024 was $21.6 million, or $0.64 loss per share
EPS: $0.64 loss per share
Result: reported results

Exact text from the filing

Celcuity Inc. (the “Company”) issued a press release regarding the Company’s financial results for the first quarter ended March 31, 2024.

View on SEC.gov

1047 earnings releases filed in the last 30 days. Browse all earnings releases →

Celcuity Inc. filing history →

Source: SEC EDGAR

accession 0001493152-24-019852

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.